Mangesh Kritya

Mangesh Kritya


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2025 in American Heart Journal
Verified
Journal Article
Closed access
SLShanmukh Sai Pavan Lingamsetty
Shanmukh Sai Pavan Lingamsetty
RMRavi Venkata Sai Krishna Medarametla
Ravi Venkata Sai Krishna Medarametla
KPKesar Prajapati
Kesar Prajapati
SJSahas Reddy Jitta
Sahas Reddy Jitta
MDMohamed Doma
Mohamed Doma
AGAndrew Michael Goldsweig
Andrew Michael Goldsweig

8 August 2025 in Structural Heart
Verified
Journal Article
Open access
THTaha Hatab
Taha Hatab
OBOsamah Badwan
Osamah Badwan
RARadwan Alkhatib
Radwan Alkhatib
ARAkiva Rosenzveig
Akiva Rosenzveig
MKMangesh Kritya
Mangesh Kritya
SKSamir R. Kapadia
Samir R. Kapadia
Tricuspid regurgitation (TR) is associated with substantial morbidity and mortality, yet it remains an undertreated entity. Transcatheter tricuspid valve replacement (TTVR) has emerged as a promising therapeutic option, with multiple novel systems demonstrating early safety and efficacy. The objective of this study is to systematically review and synthesize the clinical outcomes of transcatheter heart valve systems. A systematic search of PubMed, Embase, and Cochrane databases was conducted from database inception through March 31, 2025. Eligible studies included adult patients undergoing TTVR for severe or torrential TR, reporting at least one clinical outcome. Pooled event rates were calculated using a random-effects model. Subgroup analyses were performed by valve type, and meta-regression explored potential sources of heterogeneity. Twenty studies comprising 1017 patients were included. The mean age was 73 ± 9 years, and 71.2% were female. The weighted in-hospital and 30-day mortality were 1.37 and 2.49%, respectively. New permanent pacemaker implantation occurred in 7.98%, with highest rates observed in EVOQUE recipients (11.64%). Only 3% of patients had greater than or equal to severe TR at follow-up, and only 12% remained in New York Heart Association functional class III/IV. Subgroup analysis revealed lower in-hospital and 30-day mortality with EVOQUE but higher permanent pacemaker implantation compared to other valves. TTVR is a feasible and safe intervention for patients with severe TR, providing significant functional improvement and TR reduction. Robust, longer-term randomized controlled trials with standardized outcome reporting and clinical endpoints are urgently needed to define durable clinical benefit and guide optimal device selection for patients with severe TR.

21 November 2025 in JACC: Advances
Verified
Journal Article
Open access
FMFaysal Massad
Faysal Massad
TCTess Calcagno
Tess Calcagno
MKMangesh Kritya
Mangesh Kritya
ARAkiva Rosenzveig
Akiva Rosenzveig
THTaha Hatab
Taha Hatab
FKFred Kusumoto
Fred Kusumoto

22 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SLShanmukh sai pavan Lingamsetty
Shanmukh sai pavan Lingamsetty
MKMangesh Kritya
Mangesh Kritya
PVPriyanka Vatsavayi
Priyanka Vatsavayi
CTChenna Reddy Tera
Chenna Reddy Tera
MDMohamed Doma
Mohamed Doma
AGAndrew Michael Goldsweig
Andrew Michael Goldsweig
Background: Stroke and subclinical cerebral ischemia remain important neurological complications of transcatheter aortic valve replacement (TAVR). The Sentinel cerebral embolic protection (CEP) device is designed to capture embolic debris during TAVR, but its impact on clinical and imaging outcomes remains incompletely characterized. Methods: PubMed, Embase, and Cochrane databases were systematically searched for randomized controlled trials (RCTs) comparing Sentinel CEP versus no protection when TAVR was performed. Outcomes of interest included all stroke, disabling stroke, infarct volume by diffusion-weighted MRI in protected and unprotected areas, all-cause mortality, acute kidney injury, and major vascular complications. Risk ratios (RRs) and median differences with 95% confidence intervals (CIs) were calculated using random-effects models and trial sequential analysis (TSA) assessed evidence robustness. Results: Four RCTs including 10,986 patients were analyzed. Sentinel CEP did not significantly reduce clinical stroke (RR 0.88, 95% CI 0.69–1.12) or disabling stroke (RR 0.68, 95% CI 0.41–1.14). Pooled DW-MRI data showed a significant reduction in new ischemic lesion volume within Sentinel CEP-protected territories (difference in medians −75.7 mm3; 95% CI −130.4 to −21.0). Subgroup analyses in elderly, female, and high-surgical-risk patients revealed no benefit with Sentinel CEP. Additionally, TSA indicated that current data are underpowered for definitive conclusions. Conclusions: The Sentinel CEP device during TAVR did not significantly reduce clinical stroke but was associated with lower MRI-detected ischemic lesion volumes compared with no protection. Further adequately powered RCTs integrating clinical and imaging endpoints are needed to define its role in neuroprotection during TAVR.

23 April 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MKMangesh Kritya
Mangesh Kritya
SSShariq Shamim
Shariq Shamim
VSVaibhav Sharma
Vaibhav Sharma
ASAkshat Sahai
Akshat Sahai
TTThirugnanasambandam Thayumanavan
Thirugnanasambandam Thayumanavan
SASalman A. Arain
Salman A. Arain

15 June 2026 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
MSMarcell Szekely
Marcell Szekely
MLMaria G. Lopez-Trevino
Maria G. Lopez-Trevino
IGImre I. Gecse
Imre I. Gecse
MKMangesh Kritya
Mangesh Kritya
CKChloe Kharsa
Chloe Kharsa
MAMarvin D. Atkins
Marvin D. Atkins